Smoking Pipe or Cigarette: Which Is More Harmful? Cancer and Health Risks
- ThePiperBadik
- Aug 25
- 10 min read
Smoking Pipe vs Cigarette: Comparing Cancer, Heart, Stroke, and COPD Risks
Introduction
In this article, we will step outside the conventional framework of “a pipe is just as harmful as a cigarette” and, based on scientific data, independently evaluate and compare the risks of oral, throat, and lung cancers—as well as the other diseases mentioned in the title and related mortality—among exclusive cigarette smokers, exclusive smoking pipe users, and individuals who do not consume any tobacco products.
At this point, it must be emphasized: no tobacco product is harmless. Any form of tobacco use at least doubles the risk of oral, throat, and lung cancers—as well as the other conditions specified in the title—compared to individuals who have never used tobacco. This article in no way promotes tobacco use.
Explanation of OR and RR
Before continuing, it is useful to clarify the meaning of the OR and RR values that will appear throughout the article:
RR – Relative Risk: This refers to a comparative assessment between groups. For example, RR≈5 for exclusive pipe smokers means that the risk of developing the specific cancer is five times higher in pipe smokers compared to non-smokers.
OR – Odds Ratio: This is a method used in case-control studies to express the odds of developing cancer. For instance, OR≈3.7 indicates that the likelihood of developing the specific type of cancer is about 3.7 times higher in tobacco users compared to non-users.
Oral Cavity & Throat Cancer Risk
Cigarettes: Smoking more than one pack (20 cigarettes) per day increases the risk of oral/oropharyngeal cancer by at least fivefold compared to non-smokers, and in some cases, up to tenfold. Research conducted at the National Cancer Institute of Sri Lanka (Apeksha Hospital) (PMCID: PMC9810316, PMID: 36172654) found that individuals smoking two packs or more per day had twice the risk compared to those smoking one to two packs daily. Overall, the risk of oral squamous cell carcinoma (OSCC) was 2.93 times higher. Additionally, smoking for more than 20 years increased the OSCC risk by 3.4 times.
Smoking Pipe: The risk of head and neck cancers is at least two to three times higher compared to non-users. According to data from the international INHANCE consortium (PMCID: PMC3755640, PMID: 23817919), exclusive pipe smokers had an odds ratio (OR) of 3.71 for oral/throat cancer. The same study reported an OR of 1.65 for long-term pipe smoking and oropharyngeal (pharyngeal) cancer.
Laryngeal Cancer Risk
Cigarettes: Cigarette smoking increases the risk of laryngeal cancer by more than fivefold compared to non-smokers. For individuals smoking two packs or more daily, the risk rises dramatically, reaching 15 to 30 times higher. According to CDC data, heavy male smokers (two packs or more) face a 15–30 times greater risk of death from laryngeal cancer compared to non-users.
Smoking Pipe: Based on INHANCE consortium data, exclusive pipe smokers show an OR of 3.53 for laryngeal cancer. According to the American Cancer Society, pipe smoking is associated with a striking increase in laryngeal cancer mortality, with a relative risk (RR) of approximately 13.1. In other words, exclusive pipe smokers have a 4 to 13 times higher risk of laryngeal cancer compared to individuals who never used tobacco.
Lung Cancer Risk
Cigarettes: Meta-analyses and epidemiological studies have consistently shown that daily cigarette smokers have an 8–16 times higher risk of developing lung cancer compared to those who have never smoked or smoke only rarely. Regardless of gender, active daily smokers have a relative risk of approximately RR≈8.43. Some case-control studies reported an OR≈16 for daily smokers (PMCID: PMC3505152, PMID: 22943444). A dose-response relationship also exists: smoking one pack per day increases risk several times, while two packs or more multiplies the risk exponentially.
Smoking Pipe: A prospective study (PMID: 151732269) found that exclusive pipe smokers had a relative risk of approximately RR≈5.0 for lung cancer mortality. Similar to cigarette smoking, the risk increases with the amount of tobacco consumed: smoking 5–9 bowls per day resulted in OR≈3.2, while 10 bowls per day corresponded to OR≈6.7. Although pipe smoke is often not inhaled into the lungs, which slightly reduces the risk compared to cigarettes, exclusive pipe smokers still face a risk that is 3–6 times higher than non-users.
Type of Cancer | RR/OR in Smokers Only | RR/OR in Pipe Smokers Only |
Oral | ≥5.0× (According to non-smokers) | 3.71× (Only Pipe Smokers) |
Laryngeal Cancer | ≥5.0×; Those who smokes a lot 15–30× | 3.53× (Only Pipe Smokers) |
Lung Cancer | ~8.4× (Daily smokers) 16.0× | 5.0× / 3.2–6.7× (Only Pipe Smokers |
Illness | Risk in pipe smokers (compared to non-smokers) |
Cause Mortality | RR ≈ 1.99 |
Lung Cancer | RR = 5.00 (USA); OR = 7.9 (EU) |
Head and neck cancers (mouth, pharynx, larynx) | RR = 3.90 (orofarinks, USA); OR = 3.71 (INHANCE) |
Esophageal cancer | RR = 2.44 |
Pancreatic cancer | RR = 1.61 |
Coronary heart disease (CAD) | RR = 1.30 (ABD); RR = 1.69 (İng.) |
Stroke | RR = 1.27 (ABD); RR = 1.62 (İng.) |
Chronic obstructive pulmonary disease (COPD) | RR = 2.98 |
Illness | RR / OR Only in Pipe Smokers | RR/OR in Cigarette Smokers Only | Cigarette/Pipe Risk Ratio (approximate) |
Cause Mortality | RR ≈ 1.99 [Henley et al., 2004] | RR ≈ 2.8 – 3.0 [Thun et al., 2013] | Cigarette ≈ 50% more risky |
Lung Cancer | RR = 5.00 (USA) [Henley et al., 2004]OR = 7.9 (Avr.) | RR = 15 – 30 [CDC, 2014; Islami et al., 2015] | Smoking ≈ 3–5 times more risky |
Head and neck cancers (mouth, pharynx, larynx) | OR ≈ 3.71 (INHANCE) | OR ≈ 5.91 (INHANCE, aynı analizde) | Smoking is ≈ 60% more risky |
Esophageal cancer | RR = 2.44 [Henley et al., 2004] | RR = 5.0 – 10.0 [Sasco et al., 2004] | Smoking ≈ 2–4 times more risky |
Pancreatic cancer | RR = 1.61 [Henley et al., 2004] | RR = 2.0 – 3.5 [Boffetta & Islami, 2013] | Smoking ≈ 50–100% more risky |
Coronary heart disease (CAD) | RR = 1.30 (ABD) – 1.69 (İng.) | RR = 2.5 – 3.0 [Thun et al., 2013; CDC, 2014] | Smoking ≈ 2 times more risky |
Stroke | RR = 1.27 – 1.62 [Henley et al., 2004; Wald & Hackshaw, 1996] | RR = 2.0 – 3.5 [Thun et al., 2013; CDC] | Smoking ≈ 2 times more risky |
Chronic obstructive pulmonary disease (COPD) | RR = 2.98 [Henley et al., 2004] | RR = 10 – 12 [CDC; USDHHS, 2014] | Smoking ≈ 3–4 times more risky |
According to all available findings, when equal consumption levels are compared, there is no scientific barrier to claiming that the smoking pipe is less harmful than cigarettes. However, the benchmark should never be cigarette smokers, but rather individuals who do not use any tobacco products at all. From this perspective, the smoking pipe also carries very serious health risks.
Up to this point, cancer and disease risks have always been calculated by assuming that the risk level of non-tobacco users is zero. To present a more realistic picture, in the following sections we will also consider the lifetime risks of oral, throat, and lung cancer, cardiovascular disease, stroke, and COPD among adults who never use tobacco. Based on this comparison, we will determine the actual health risks faced specifically by smoking pipe users.
Illness | Lifetime Risk (%) | Gender Difference / Note | Resources |
Oral Cavity | ~1.0% | Slightly higher in men; risk increases with alcohol consumption | ACS, IARC, INHANCE |
Throat Cancer | ~0.05 – 0.1% | ~0.5% in the total population in men; much less common in non-smokers | SEER, CDC, IARC |
Lung Cancer | ~1.0 – 1.5% | May be slightly higher in men (1.3%), 1.0–1.2% in women | NCI, Canadian Cancer Society |
Coronary heart disease (CAD) | Male: 20–25% Female: 10–15% | Framingham and ESC data for individuals over 40 | Framingham, CDC, ESC |
Stroke | ~15 – 20% | Risk is higher in Eastern Europe and Türkiye (~25%); this rate decreases in non-smokers | WHO, Global Burden of Stroke |
Chronic obstructive pulmonary disease (COPD) | ~2 – 6% | May increase in those exposed to passive smoke, occupational dust, and air pollution | BOLD, NHANES, GOLD |
Illness | Tobacco-free (% of lifetime) | RR/OR in Pipe Smokers | Real Risk (≈ %)(RR × Base Risk) |
Oral Cancer | ~1.0% | OR ≈ 3.7 | ≈ 3.7% |
Larynx Cancer | ~0.1% | OR ≈ 3.5 – 13.0 | ≈ 0.35% – 1.3% |
Lung Cancer | ~1.5% | RR ≈ 5.0 | ≈ 7.5% |
Coronary heart disease (CAD) | Male: 25% - Female: 15% | RR ≈ 1.3 – 1.7 | Erkek: 32.5 – 42.5%Kadın: 19.5 – 25.5% |
Stroke | ~20% | RR ≈ 1.3 – 1.6 | ≈ 26 – 32% |
Chronic obstructive pulmonary disease (COPD) | ~4% (avarage) | RR ≈ 2.5 – 3.0 | ≈ 10 – 12% |
Illness | Tobacco-free (% of lifetime) | RR/OR in Pipe Smokers - Reel Risk % | Smoker/OR → Real Risk (%) |
Oral Cancer | ~1.0% | OR ≈ 3.7 → 3.7% | OR ≈ 6.0 – 10.0 → 6 – 10% |
Larynx Cancer | ~0.1% | OR ≈ 3.5 – 13.0 → 0.35 – 1.3% | OR ≈ 10 – 30 → 1.0 – 3.0% |
Lung Cancer | ~1.5% | RR ≈ 5.0 → 7.5% | RR ≈ 15 – 30 → 22.5 – 45% |
Coronary heart disease (CAD) | Male: 25% Female: 15% | RR ≈ 1.3 – 1.7 → 32.5 – 42.5%19.5 – 25.5% | RR ≈ 2.5 – 3.0 → 62.5 – 75%37.5 – 45% |
Stroke | ~20% | RR ≈ 1.3 – 1.6 → 26 – 32% | RR ≈ 2.0 – 3.5 → 40 – 70% |
Chronic obstructive pulmonary disease (COPD) | ~4% | RR ≈ 2.5 – 3.0 → 10 – 12% | RR ≈ 10 – 13 → 40 – 52% |
Real Risk = Baseline (Never Smokers) x RR
Real Values are approximate; multiplication was performed at the intervals where RR/ORs become precise. Although the average baseline risk for COPD is 4%, this rate can vary by 2-6% in some regions.
Risks are approximate and averaged from academic sources. The reference group is adults who have never used tobacco.
Illness | RR/OR in Pipe Smokers | RR/OR in CigaretteSmokers | Cigarette/Pipe Relative Ratio |
Oral Cancer | OR ≈ 3.7 | OR ≈ 6 – 10 | 1.6 – 2.7 times more risky |
Larynx Cancer | OR ≈ 3.5 – 13.0 | OR ≈ 10 – 30 | 1 – 3 times more risky |
Lung Cancer | RR ≈ 5.0 | RR ≈ 15 – 30 | 3 – 6 times more risky |
Coronary heart disease (CAD) | RR ≈ 1.3 – 1.7 | RR ≈ 2.5 – 3.0 | 1.8 – 2.3 times more risky |
Stroke | RR ≈ 1.3 – 1.6 | RR ≈ 2.0 – 3.5 | 1.5 – 2.7 times more risky |
Chronic obstructive pulmonary disease (COPD) | RR ≈ 2.5 – 3.0 | RR ≈ 10 – 13 | 3.3 – 5.2 times more risky |
Oral Cancer
Cigarette smokers face on average twice the risk compared to those who smoke only pipes. This difference is explained by the fact that, although pipe smoke is often held in the mouth, pipe smokers generally do not inhale the smoke into their lungs.
Laryngeal Cancer
Here, the difference depends on the intensity of consumption. Those who smoke more than one pack of cigarettes per day face three times higher risk compared to those who smoke 3–4 bowls of pipe tobacco daily. However, in very heavy pipe smokers, the risk eventually approaches that of cigarette smokers.
Lung Cancer
The most striking difference is observed here: cigarette smokers face 3 to 6 times higher risk compared to exclusive pipe smokers. This is because cigarette smoke is inhaled deeply and directly into the lungs, whereas pipe smoke typically is not.
Cardiovascular Diseases (CVD)
Cigarette smokers have approximately twice the risk of heart disease compared to pipe smokers. This is primarily due to systemic inflammation and arterial blockage caused by cigarette smoke.
StrokeCompared to pipe smoking, cigarettes increase the risk of stroke by 50% to 170%. This difference becomes more pronounced with long-term smoking.
Chronic Obstructive Pulmonary Disease (COPD)
Pipe smokers are also at risk of COPD; however, compared to cigarette smokers, their risk is 3–5 times lower. This is because COPD is largely associated with frequent and deep inhalation of smoke—a habit typical of cigarette smoking.
In conclusion, looking at all this data, cigarette smokers face disease risks that are on average 2 to 5 times higher than those of pipe smokers. While it is now evident that pipe smoking is less harmful than cigarette smoking, it must never be forgotten that improper use—such as smoking more than five bowls per day, inhaling the smoke, or misusing the pipe—can make the risks equal or even greater than those of cigarettes. Moreover, compared to individuals who do not use any tobacco products at all, even exclusive pipe smokers face significantly elevated health risks.
If you found this article useful, don’t forget to like, share, and leave a comment.

Source:
American Cancer Society. (2023). Lifetime Risk for Selected Cancers. Retrieved from https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html
Boffetta, P., & Islami, F. (2013). Effect of smoking on cancer and cardiovascular disease. Current Opinion in Lipidology, 24(6), 576–581. https://doi.org/10.1097/MOL.0000000000000024
Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., ... & BOLD Group. (2007). International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. The Lancet, 370(9589), 741–750. https://doi.org/10.1016/S0140-6736(07)61377-4
Canadian Cancer Society. (2022). Lifetime risk of cancer. Retrieved from https://cancer.ca/en/cancer-information/cancer-101/cancer-statistics/lifetime-risk
Centers for Disease Control and Prevention. (2014). The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services. https://www.ncbi.nlm.nih.gov/books/NBK179276/
Centers for Disease Control and Prevention. (2018). Surveillance for Cancers Associated with Tobacco Use—United States, 2010–2014. Morbidity and Mortality Weekly Report, 67(SS12), 1–42. https://doi.org/10.15585/mmwr.ss6712a1
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008). General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation, 117(6), 743–753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579
de Marco, R., Accordini, S., Cerveri, I., Corsico, A., Sunyer, J., Neukirch, F., ... & ECRHS Group. (2004). An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax, 59(2), 120–125. https://doi.org/10.1136/thorax.2003.011163
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., ... & Murray, C. J. L. (2019). The global burden of neurological disorders: translating evidence into policy. The Lancet Neurology, 18(5), 418–428. https://doi.org/10.1016/S1474-4422(19)30029-8
Henley, S. J., Thun, M. J., Chao, A., & Calle, E. E. (2004). Association between exclusive pipe smoking and mortality from cancer and other diseases. Journal of the National Cancer Institute, 96(11), 853–861. https://doi.org/10.1093/jnci/djh145
International Agency for Research on Cancer (IARC). (2004). Tobacco smoke and involuntary smoking (Vol. 83). Lyon, France: World Health Organization. https://publications.iarc.fr/94
International Agency for Research on Cancer (IARC). (2012). Personal habits and indoor combustions (Vol. 100E). Lyon, France: World Health Organization. https://publications.iarc.fr/139
Islami, F., Torre, L. A., & Jemal, A. (2015). Global trends of lung cancer mortality and smoking prevalence. Translational Lung Cancer Research, 4(4), 327–338. https://doi.org/10.3978/j.issn.2218-6751.2015.08.04
Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: risk factors, prevalence, and future trends. The Lancet, 370(9589), 765–773. https://doi.org/10.1016/S0140-6736(07)61380-4
National Cancer Institute. (2021). SEER Cancer Statistics Review, 1975–2018. Retrieved from https://seer.cancer.gov/csr/1975_2018/
Thun, M. J., Carter, B. D., Feskanich, D., Freedman, N. D., Prentice, R., Lopez, A. D., ... & Gapstur, S. M. (2013). 50-year trends in smoking-related mortality in the United States. New England Journal of Medicine, 368(4), 351–364. https://doi.org/10.1056/NEJMsa1211127
World Health Organization (WHO). (2023). Global Stroke Factsheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/stroke
Wyss, A., Hashibe, M., Chuang, S. C., Lee, Y. C. A., Zhang, Z. F., Yu, G. P., ... & Brennan, P. (2013). Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. American Journal of Epidemiology, 178(5), 679–690. https://doi.org/10.1093/aje/kwt029
Hakan Badik
Comments